The clinical evidence
The entire human evidence base for MT-II fits in a short list: one 3-person tanning pilot, two small erectile-function…
What the studies really showed, and how to read them
The entire human evidence base for MT-II fits in a short list: one 3-person tanning pilot, two small erectile-function studies, and a body of animal work. This unit examines each, then teaches the skill that matters most, reading a small clinical study honestly, so you can judge MT-II claims yourself.
The arc also tells a bigger story: how a messy research compound produced one genuinely approved drug, PT-141, through deliberate redesign rather than wishful thinking.
Key terms
The whole evidence base, mapped
Before examining individual studies, it helps to see the entire human evidence base at once, plotted by quality and impact. The striking thing is how sparse and clustered it is: a few small points, none of them a large trial, for a drug used by many thousands of people.
Two facts jump out. The study most relevant to tanning (top of the chart) is the weakest in quality. The studies highest in quality are about sexual function, not tanning, and enrolled 10 men each. There is no point anywhere near the strong-and-relevant corner. For the use MT-II is actually marketed for, the rigorous evidence simply does not exist.
AdvancedWhy no large MT-II trial was ever run
What the record shows is where the work went: a 2006 history states that melanotan II was tested clinically for erectile dysfunction and that a new analogue, PT-141, had entered phase I and II trials and was scheduled for phase III. The usual explanations for the gap, that a cosmetic indication attracts little trial funding and that non-selectivity made MT-II a poor candidate, are reasonable readings and not statements any source here makes. What is certain is the outcome: the compound was never carried into the phase 2 and 3 trials that would have produced real efficacy and safety data.